This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate From OECD And EU

SHANGHAI, Aug. 23, 2011 /PRNewswire-Asia/ -- WuXi AppTec announced today that its Bioanalytical Services (BAS) unit had received a certificate of Good Laboratory Practice (GLP) from the Organization for Economic Cooperation and Development (OECD) and the European Union (EU).  

The certificate states that WuXi's BAS facility in Shanghai is able to carry out ADME (absorption, distribution, metabolism, and excretion) studies, toxicokinetic and pharmacokinetic studies, and hERG assay and biomarker studies with respect to OECD and EU principles of Good Laboratory Practice.  Award of the certificate followed a thorough review of the facility operations and records on May 9-11, 2011, by Belgian authorities.  

This represents WuXi's third successful audit of its bioanalytical lab by regulatory authorities.  The facility also passed a bioequivalence study inspection by the U.S. Food and Drug Administration (FDA) in March 2009 and an inspection by China's State Food and Drug Administration (SFDA) supporting the certification of WuXi's GLP toxicology operation in Suzhou.  The BAS laboratory is now certified by the SFDA and OECD to provide GLP-compliant support for nonclinical studies.  In addition, this laboratory is certified by the OECD to support clinical trials for small-molecule and biologics pharmacokinetics and biomarker analysis.

WuXi's Bioanalytical Services (BAS) was established in 2005.  BAS provides GLP-compliant services to analyze small-molecule drugs using liquid chromatography/mass spectroscopy and to measure biomarker/biologics and antibody immunogenicity using immunochemistry.  It is the only bioanalytical laboratory in China to have passed SFDA, OECD, and FDA GLP inspections.

"We are very pleased to have passed this OECD/EU inspection," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec.  "WuXi will continue to pursue the highest levels of quality and transparency to meet and exceed international requirements."

"As a GLP-compliant facility, BAS always treats quality and compliance as our highest priorities," commented Dr. Jinsong Xing, Vice President of BAS of WuXi AppTec.  "We maintain GLP readiness through continuous training, review of technology, and rigorous proficiency testing.  Our quality control team thoroughly reviews all data and closely monitors the facility for compliance on a daily basis."

About WuXi PharmaTech and WuXi AppTec

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit: http://www.wuxiapptec.com .

For more information, please contact:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs